Indivior PLC (NASDAQ:INDV) Declares $8.13 Special Dividend

Indivior PLC (NASDAQ:INDV) announced a special dividend on Thursday, September 17th. Stockholders of record on Friday, October 30th will be given a dividend of 8.13 per share on Friday, November 6th. The ex-dividend date is Friday, October 30th.

Indivior Trading Up 3.9%

Shares of INDV stock opened at $35.69 on Friday. The company has a market cap of $4.21 billion, a P/E ratio of 12.79 and a beta of 0.82. The firm has a fifty day moving average price of $37.70 and a 200 day moving average price of $36.10. Indivior has a 12 month low of $22.22 and a 12 month high of $42.81.

Indivior (NASDAQ:INDV) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share for the quarter. The company had revenue of $343.00 million for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%. On average, equities analysts forecast that Indivior will post 3.66 EPS for the current year.

Analyst Upgrades and Downgrades

INDV has been the topic of a number of recent analyst reports. Barclays dropped their price objective on Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a report on Wednesday, August 5th. Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a report on Monday, June 29th. Craig Hallum reiterated a “buy” rating and issued a $53.00 price target on shares of Indivior in a research note on Tuesday, August 4th. Finally, Weiss Ratings raised shares of Indivior from a “hold (c+)” rating to a “buy (b-)” rating in a report on Friday, September 4th. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, Indivior has a consensus rating of “Moderate Buy” and an average target price of $45.17.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company focused on developing and commercializing medicines for addiction and serious mental health disorders. Its portfolio is primarily centered on treatments for opioid use disorder, with an emphasis on products designed to support recovery, reduce illicit opioid use and address the risk of overdose.

The company’s key products include SUBOXONE sublingual film, a buprenorphine-and-naloxone treatment for opioid use disorder; SUBLOCADE, a long-acting injectable form of buprenorphine; and OPVEE, a nalmefene nasal spray intended for the emergency treatment of opioid overdose.